K2M, a spinal device company, launched the VIKOS cervical allograft system, the company's first biologics product, according to a company news release.
VIKOS was developed to support physicians treating cervical pathologies with cortical ring and cortical-cancellous implant options of several sizes. The implants are designed with lordotic options for sagittal alignment and are used with LifeNet Health's PRESERVON technology for equipment storage.
Read K2M's release on VIKOS.
Read other coverage on K2M:
- K2M Receives FDA Clearance for Anterior Lumbar Stabilization System
- K2M Introduces Two Minimally Invasive Spine Surgery Products
- Welsh Carson Acquires Spinal Device Company K2M
VIKOS was developed to support physicians treating cervical pathologies with cortical ring and cortical-cancellous implant options of several sizes. The implants are designed with lordotic options for sagittal alignment and are used with LifeNet Health's PRESERVON technology for equipment storage.
Read K2M's release on VIKOS.
Read other coverage on K2M:
- K2M Receives FDA Clearance for Anterior Lumbar Stabilization System
- K2M Introduces Two Minimally Invasive Spine Surgery Products
- Welsh Carson Acquires Spinal Device Company K2M